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Abstract: 
Aim: To identify factors associated with treatment failure of presumed ocular 
tuberculosis in an area of low endemic prevalence 
Methods: A retrospective cross-sectional study was performed for 213 patients 
with presumed ocular tuberculosis from a database from a tertiary referral eye 
hospital in the UK. A forward conditional logistic regression model was 
constructed incorporating demographics, baseline characteristics, and different 
cut offs of QFT to identify significant factors accounting for the variability of the 
response variable (“failure”) across the whole group.  Treatment failure was 
defined as the recurrence of inflammation or inability to taper steroids within six 
months of completion of anti tubercular therapy (ATT) or after at least 6 months 
of treatment in the non-ATT group.  
Results:126 (65.49%) patients received at least six months of ATT. Within the 
model, patients with QFT values >1.50 (OR=0.25, 95% CI=0.11 to 0.56, 
p=0.001) had less risk of treatment failure as against those with QFT values 
between 0.35 and 1.50. Steroid sparing immunosuppressive agents reduced 
the chances of treatment success (OR=25.6, 95% CI: 8.7 to 100.8, p<0.001). 
This effect persisted even after adjusting for potential confounding factors. 
Conclusions: Patients with higher values of QFT (>1.5) are more likely to be 
associated with treatment success with ATT. In our model, steroid sparing 
immunosuppressive agents reduced the chances of success, in both ATT and 
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non ATT treated patients. It is unclear whether this effect reflects the intrinsic 
underlying severity of disease (i.e. study bias), or whether steroid sparing 
immmunosuppresive agents mitigate against successful ATT therapy.  
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Introduction 
Tuberculosis (TB) remains a major global health problem with an estimated 8.6 
million people who have developed TB and 1.3 million deaths in 2012.[1] Among 
the developed western countries, the UK has one of the highest incidence rates 
of 13.9/100,000 reported in 2012. The risk factors include young age, male 
gender and being born outside of the UK. Increased and rising rates are seen in 
the population from the Indian subcontinent and in those who have been resident 
in the UK for long periods of time prior to their TB diagnosis.[2]  
The clinical diagnosis of ocular TB is difficult since clinical signs and symptoms 
can mimic other conditions.[3 4] The ophthalmologist relies on a combination of 
clinical history, ocular signs, systemic examination by a physician, and screening 
investigations such as chest radiographs and the tuberculin skin test (TST). [3 4] 
A definite diagnosis of TB uveitis can be confirmed by performing acid-fast 
smears, mycobacterial cultures, or polymerase chain reaction-based assays on 
ocular fluid samples.  
Interferon gamma release assays (IGRAs) are new immune-based in vitro tests 
based on the detection of interferon gamma (IFN-γ) released by sensitized T 
cells on stimulation with very specific antigens, early secretory antigen target-6 
and culture filtrate protein-10, for detecting Mycobacterium tuberculosis (MTb) 
infection. [5 6] Two commercially available IGRAs include the T-Spot TB test 
(based on the ELISpot technology to directly count the number of IFN-γ-secreting 
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T cells) and the Quantiferon TB Gold In-Tube test (QFT: based on the ELISA 
technology, which measures the concentration of IFN-γ secretion; Cellestis 
Limited, Carnegie, Victoria, Australia). [7] We examined the predictive failure 
related to treatment failure or success  in a TB-non endemic, cosmopolitan 
population. 
Methods 
This was a retrospective review of health records of patients seen at a large 
tertiary uveitic centre in central London, UK. The study was approved by the 
institutional review board (ROAD 14/012) and all the research adhered to the 
tenets of the Helsinki declaration. 
The clinical case definition of presumed intraocular tuberculosis were 
broad, but entailed all patients with uveitis where the diagnosis of TB 
uveitis could be considered based on one or more of the broad clinical 
signs suggested by Gupta et al in 2007.[3] In addition, all patients had had a 
diagnostic work –up to exclude other diagnoses. Data collected included 
information on demographics, clinical findings, investigations and therapeutic 
regimens. Patients at presentation were examined for signs suggestive of ocular 
tuberculosis by the uveitis team. All patients with presumed TB with a positive 
QFT  were included in the study. All patients with positive QFT and active 
inflammation suggestive of presumed ocular tuberculosis were further referred to 
a respiratory physician. Based on the physician’s discretion and the 
ophthalmologists’ reommendations, anti-tubercular therapy (ATT) was 
initiated. We have taken a “novel” approach to this problem of selection 
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bias for instituting ATT  by looking at an expanded dataset of patients 
where the diagnosis of TB uveitis could reasonably be considered, based 
upon clinical features, demographic risk factors, and where investigations 
have excluded other diagnoses. By adding patients who do, and do not get 
ATT treatment we add power to our analysis in the form of a multivariate 
logistic regression analysis.  The decision not to give ATT was not based 
on intolerance to medications. 
Important definitions used were: 
QFT: Positivity was assessed according to the Centre for Disease Control (CDC) 
recommendations.[8] (positive >0.35 IU/m). The test was not adjusted or 
considered inappropriate if the patient was on concurrent oral 
corticosteroids as the CDC has not recommended any specific criteria for 
assessment of QFT results based on concurrent steroid therapy. However, 
we acknowledge the fact that oral corticosteroid treatment at the time of 
asssessment can act as a potential confounder for the QFT value and we 
hence performed the statistical test to study the impact of the oral steroids 
or steroid sparing immunosuppressive therapy at time of QFT assessment.  
 
Definition of failure: Treatment failure was defined as the inability to taper oral 
corticosteroids to less than 10mg/ day or topical steroids to less than two times 
per day or the inability to stop the steroid sparing immunosuppressive agent or 
persistence or recurrence of inflammation within the first six months of 
completion of ATT.  For the patients not on ATT, treatment failure was defined by 
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the inability to taper medications to the same levels of systemic and topical use 
at the same follow up duration as the ATT treated group. The definition was 
adapted based on the absence of current conventional guidelines for 
diagnosis and treatment of presumed ocular tuberculosis. The final follow 
up for assessment of treatment failure or success was based on the 
inflammation or recurrence within the first six months of completion of ATT 
or within six months of tapering or stopping oral corticosteroids for the 
non ATT group. 
Statistical methods: Qualitative variables were expressed as percentages. 
Quantitative variables were expressed as mean values ± standard deviation (SD) 
or as median values (range).  A binary logistic regression model was built with 
the treatment failure result as the dependent variable. The selection of variables 
in the final model was performed by a forward-conditional method, with 
significance levels of ≤0.05 for inclusion and ≥0.1 for exclusion, and in addition 
putting age, gender and QFT value into the equation. Overall model fit was 
assessed by the Nagelkerke R2 and the C-index. A ROC (Receiver Operating 
Characteristics) plot was constructed to assess the specificity and sensitivity of 
the logistic regression variables for treatment failure.  Results were considered 
statistically significant when p < 0.05. Data were analysed using Stata ⁄ SE, 
version 13.0 (StataCorp, College Station, TX, USA). 
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Results 
A total of 365 patients were identified from our uveitis database with a diagnosis 
of presumed ocular tuberculosis. 309 (81.64%) patients underwent QFT out of 
which 220 (60.44%) patients were QFT positive and were included in the study 
(Figure 1). 7 patients had insufficient follow up and were excluded from further 
analysis. 213 patients with positive QFT were further grouped into those who 
received ATT (n=136, 63.85%) or no ATT (n=77, 36.15%) ( Figure 1A). Figure 
1B summarises success and failure in each subgroup with and without oral 
steroids or steroid sparing immunosuppressive therapy.  
38 (18.27%) patients were on oral steroids or steroid sparing 
immunosuppressives at time of  QFT. The mean value of QFT was 7.32±6.71 in 
patients not on prior steroids and/or steroid sparing immunosuppressives and 
6.47±5.09 for those on prior corticosteroid and/or steroid sparing 
immunosuppressives (p=0.816, Mann Whitney test). The mean age of the 
population was 45.99±15.61 years with a preponderance of males and bilateral 
presentation (Table 1). Patients receiving ATT were significantly younger 
(p<0.001), and more frequently of Asian (p=0.016) descent. There was no 
statistically significant association between bilaterality and patients receivng ATT 
(p=0.269) 
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Comparing the clinical phenotypes of patients who received ATT therapy versus 
those who did not, those with ocular features of retinal vasculitis (p=0.014), 
serpiginous choroiditis (p=0.015), and panuveitis (p=0.009) in conjunction with 
positive QFT were more likely to be treated with ATT (Table 2A) compared to 
those without such features.  Patients with milder forms of uveitis, such as 
anterior (p<0.001) or intermediate uveitis (p<0.001) were proportionally under-
represented in the treatment group. There was no specific preference to institute 
ATT based on qualitative changes suggestive of old healed pulmonary TB seen 
on chest radiography (p=0.115) or quantitative value of the QFT (p=0.90) (Table 
2B).  
Treatment details: For the patients in the ATT treated group: ATT was 
instituted by the respiratory physicians. Based on the preference of the 
physician, different ATT regimes was instituted. Out of 136 patients in ATT 
treated group, there were 53(39.0%) patients with six months of ATT, 
19(14.0%) and 54(39.7%) with 9 and 12 months of ATT respectively 
highlighting the heterogeneity in the treatment preference by the 
physicians. Also, 10(7.3%) patients had only three months of Isoniazid and 
Rifampicin prophylaxis (like Directly Observed Therapy –DOT- short course 
therapy for TB) before initiating steroid or steroid sparing 
immunosuppressive therapy. Due to relentless clinical progression, steroid 
sparing immunosuppressive agents were given in 15 (11.0%) patients. 
While 93 (68.38%) patients received conventional ATT regimen comprising 
of two months of Rifampicin (10mg/kg/day), Ethambutol (25mg/kg/day), 
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Isoniazid (5mg/kg/day) and Pyrazinamde (25mg/kg/day) followed by six to 
ten months of Rifampicin (10mg/kg/day) and Isoniazid (5mg/kg/day), 43 
(21.62%) patients had 2 months of Rifampicin, Isoniazid, Pyrazinamide and 
Moxifloxacin (7.5-10mg/kg/day) followed by Rifampicin, Isoniazid and 
Moxifloxacin as advised by one of the treating chest physicians. This was 
noted to be a change in practice from the regimen most commonly used in 
2009/10 when moxifloxacin was rarely used. The type of regimen did not 
had any statistically significant impact on the treatment outcome. 
 
Bivariate and logistic regression analysis was done to identify the risk factors for 
treatment failure for the entire cohort of 213 patients. Oral corticosteroids did 
not have any influence on the failure or success of therapy on bivariate 
analysis (p=0.109) and hence was taken in the multivariate regression 
analysis. The model for logistic regression analysis after inputing selective 
variables ( as listed in Table 3) from bivariate analysis was accurate (C index = 
0.796, 95% CI = 0.718 to 0.874, pHosmer Lemeshow = 0.445) (Table 3). 
Patients receiving  steroid sparing immunosuppressive agents had statistically 
high chances of failure (OR=25.6, 95% CI: 8.7 to 100.8, p<0.001) across the 
whole cohort.   
 
Mean QFT value for ATT group was 7.13 ((±5.96) and for non ATT group 
was 7.02 (±7.22).  As the conventional cut off for QFT is 0.35, we explored 
newer cut off values starting from 1.00 to 3.00. After analysing different cut off 
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values at 1.00, 1.50, 2.00, 2.50 and 3.00 of QFT, patients with QFT values 
>1.50 (OR=0.25, 95% CI=0.11 to 0.56, p=0.001) had less risk of treatment failure 
as against those with QFT values between 0.35 and 1.50. ESR was a significant 
factor in univariate analysis but not in regression analysis possibly due to the 
difference in age of the patients in the treatment group (patients without ATT 
were older = 50.91±17.62 years compared to those who had ATT  43.21±13.65 , 
p=0.001).  
We further compared the cohort of patients who received steroid sparing 
immunosuppressive agents with the group who did not have (Table 4). Patients 
with bilateral disease and panuveitis were more likely to receive steroid sparing 
immunosuppressive agents, while patients with anterior uveitis were less likely to 
receive oral corticosteroids therapy (p<0.067). 15 patients (11.03%) were on 
concurrent steroid sparing immunosuppressive agents and ATT.  
 
ROC (Receiver Operating Characteristics) and sensitivity and specificity plots 
were performed after logistic regression analysis (Figure 2) to assess the ability 
of the regression model to correctly classify patients into treatment success or 
failure and also to assess the ROC with a new cut off value for QFT. Using 
different cut off values for QFT as described above, the forward:conditional 
model included a cut off value of 1.5, as this was found to maximize the 
predictive ability of the model versus the other values tried (1.0, 2.0, 2.5 and 3.0). 
The predicted probability of the model described in table 3 had an area 
under ROC curve (C-index) of 0.796 (Figure 2A). Patients who received ATT 
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and had QFT >1.50 had AUC (Figure 2B) of 0.804 (95% CI=0.690 to 0.924) 
and those with QFT<1.50 had AUC (Figure 2C) of 0.8469 (95% CI: 0.659 to 
1.000). For non ATT group, patients with QFT of >1.50 had AUC (Figure 2D) 
of 0.646 (95% CI: 0.443 to 0.864) and those with QFT<1.50 had AUC (Figure 
2E) of 0.616 (95% CI: 0.354 to 0.846). ATT was not a statistically significant 
predictor for failure or treatment success. Treatment with ATT or oral 
corticosteroids alone or in combination in patients with positive QFT and any 
combinations of clinical signs reduced the likelihood of treatment failure but did 
not reach statistically significant sensitivity or specificity levels (Figure 2).  
 
Discussion 
Diagnosis and management of tuberculous uveitis remains a conundrum for most 
clinicians. It may be a manifestation of a true infection or a hypersensitivity 
reaction to an extraocular infection. [3] Mycobacterium culture or histopathology 
remain as gold standard but have inherent limitations due to low test yield and 
difficulty in obtaining samples due to poor access to ocular tissue. [9] PCR is a 
well-established technique but its usefulness remains limited. [3] Fundus 
fluorescein angiography, indocyanine green angiography, ocular coherence 
topography, ultrasonic biomicroscopy and computed tomography are all used as 
diagnostic adjuncts to monitor the progress and complications of uveitis but their 
utility as  primary diagnostic tools for tuberculous uveitis remain limited.[10 11 12] 
IGRA are considered highly specific for Mycobacterium tuberculosis because 
they are not confounded by prior vaccination for TB. However concerns have 
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been raised [13] about the sensitivity of QFT  for detection of latent TB infection 
and superiority to traditional tuberculin skin test. [14] Kurup et al [15]  reported no 
demonstrable advantage of QFT over tuberculin skin test for detection of latent 
TB infection in patients with granulomatous uveitis. Recently, Ang et al 
recommended Gold In-Tube as the first-line test in preference to T-SPOT.TB [16] 
but also demonstrated that QFT was not superior to tuberculin skin test in 
sensitivity as a screening test or first-line study in TB-related uveitis.[17] Similarly, 
Babu et al showed that QFT is not specific for intraocular TB.[18]   QFT was 
positive in 70% of our presumed ocular tuberculosis patients. It remains a 
valuable tool in diagnosis and management of disease in regions with low 
prevalence rates of tuberculosis compared to Singapore and India with high 
prevalence rates of both pulmonary and extra pulmonary tuberculosis where 
other ancillary tests are likely to be positive.  
The treatment of ocular TB is largely presumptive and there are no randomised, 
controlled clinical trials or locally recommended guidelines to guide the 
management of ocular TB. Specifically, there are no randomised, controlled 
clinical trials looking at the role of ATT in treatment of ocular TB. This has 
lead to a wide range of treatment practice patterns which have been 
reported in the literature. Like in the UK, there are no national TB guidelines 
about ocular TB diagnosis and treatment in many non endemic regions 
including Canada and USA. There are conflicting reports and literature on 
the use of mono versus multiple drug therapy and there is also signifcant 
debate about treatment duration with ATT (6-18months). Clinical outcomes 
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are therefore inconsistent due to lack of a clinical definition for the exact 
diagnosis of ocular TB, concomitant cortiocosteroid therapy and variation 
in severity of ocular inflammation prior to initiating treatment [19 20].  
 
In our current study, diagnosis was made by the clinician and only those 
cases who had positive QFT or strong clinical suspicion of intraocular 
tuberculosis, were referred to respiratory physicians for further 
consultation and initiating ATT. Patients with stable or mild anterior uveitis 
and retinal vasculitis were not referred for ATT due to less visual morbidity, 
however patients with posterior or pan uveitis or recurrent intermediate 
uveitis were referred for a therapeutic trial of ATT. The final decision to 
initiate ATT was based on the discretion of the treating physician. Similar 
variation in practice occurs in regards to drugs, duration and use of concurrent 
local or systemic steroids. Systemic steroids have been used and recommended 
in other forms of extra pulmonary tuberculosis [21 22] ; they are used in ocular 
tuberculosis uveitis to control persistent inflammation or retinal vasculitis but their 
role is unproven.  
In our study, the use of steroid sparing immuosuppressive therapy 
increased the likelihood of treatment failure. It is difficult to ascertain the 
exact cause. One possible hypothesis is that this agents suppress host 
immune function and this can be disadvantageous in TB infection. In our 
series, a significant proportion of patients were on prior corticosteroid 
therapy before ATT was commenced. Clinical phenotypes represented by 
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positive QFT and those that failed to response to ATT and oral 
corticosteroid therapy may be the “immune mediated” form and possibly 
require prolonged immunosuppression and hence steroid sparing 
immunosuppressives did not have a positive impact on the treatment 
outcome.  
 
Secondly, the failure in patients treated with steroid sparing 
immunosuppresives could be attributed to under treatment with 
corticosteroids or rapid tapering of the oral steroids before the cumulative 
effect of steroid sparing agents sets in. Also the effective dose of 
corticosteroid is half the actual dose in the presence of Rifampicin which 
affects the metabolism of corticosteroids. Rifampicin increases the plasma 
clearance of prednisolone by 45% and reduces drug bioavailability in 
tissues by 66% [23]  which needs to be considered when deciding the dose 
of prednisolone. In addition, drug resistance to ATT, reinfection, or 
immunological response to tubercular antigens released during ATT are 
other possible reasons for worse outcomes when immununosuppressives 
were used. Recurrence of disease in up to 25% of cases is a recognised 
phenomenon and certain clinical phenotypes like intermediate uveitis and 
retinal vasculitis represent increased risk.[24 25 26] There is a reasonable 
possibility that these cases irrespective of QFT results were not associated 
with tubercular uveitis and they represented non infectious posterior 
uveitis requiring prolonged immunousuppression hence there was failure 
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to respond to steroid therapy.  Our findings that steroid sparing 
immunosuppressives in ATT groups increased the likelihood of treatment 
failure could be an artifactual finding of study bias, and may simply reflect 
the underlying severity of uveitis.  
 
According to our model, treatment success as per our definition of succesful 
steroid taper was optimal with a QFT cut-off of 1.5 IU/ml. A similar trend was 
seen by Gineys et al [27] in their small cohort but they concluded the cut off value 
was more than 2 IU/ml. The authors demonstrated a higher success rate with 
ATT in patients with highter cut off value (7.67IU/ml v/s 1.22 IU/ml with 
p=0.026 by Wilcoxon test). The authors included patients with varying 
degree and types of inflammation in their case series as there were 7 
patients with scleritis, 34 patient with panuveitis, 15 patients with posterior 
uveitis, 14 patients with intermediate uveitis and 15 patients with anterior 
uveitis. There were 42 patients with positive QFT. 54 patients with negative 
QFT, 12(29%) patients receiving concurrent oral steroids in the positive 
QFT group and 14(26%) patients receiving oral steroids in the QFT negative 
group. The authors evaluated the treatment success based on a therapeutic 
trial with ATT. Thus, there is emerging evidence that laboratory cut-off values 
(0.35 IU/mL) set by the manufacturer are possibly too low for non endemic areas. 
It may be time to revisit and set up higher cut off values if one is going to 
recommend ATT treatment  based upon a positive IGRA in the context of 
presumptive clinical signs of tuberculous uveitis.  
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The ROC curves demonstrated that ATT was not a significant predictor of 
success in our models and that the ROC curves were comparable in the ATT 
versus the non ATT treated group in respective subgroups of patients with QFT 
of <1.50 and QFT of >1.50. The success rate would have been better if we had 
treated only those patients with QFT > 1.5. This conclusion can only be inferred 
post analysis. However, the equivalence of success rates between the ATT 
treated group and the non ATT treated group (presumed non infective) suggests 
that the clinicians are doing a reasonable job in identifying those patients who will 
do well with ATT therapy.  
In summary, we present one of the largest clinical case cohort studies of 
presumptive ocular tuberculosis with positive QFT in a population with low 
endemic prevalence. Positive QFT provides useful information and directs 
towards the use of ATT in the presence of other clinical signs suggestive of 
presumptive ocular tuberculosis. However, based on our results, it seems 
the cut off value of QFT needs further investigation in low endemic regions. 
Our findings that steroid sparing immunosuppressive therapy increased 
the likelihood of treatment failure is intriguing. Whilst it could be an 
artifactual finding, and simply reflect the underyling severity of uveitis, we 
propose an alternative hypothesis, namely that immunusuppression do 
increase the likelihood of treatment failure in TB uveitis. This is biologically 
plausible as immunuosuppressivs suppress host immune function. There 
are no randomised control trials explicitly looking at the benefit of oral 
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steroids or steroid sparing immunosuppression in tuberculous uveitis. In 
fact, the evidence base for the benefit of oral steroids in TB associated 
uveitis is extremely weak, largely resting on expert opinion and very low 
quality evidence. [28] 
Indeed, this study has inherent limitations of being retrospective in nature 
with no defined treatment duration. Prospective and idealy randomised 
control trials are urgently needed in order to investigate this further. Such 
studies are likley to require a multicentre approach in order to compare 
results in TB endemic and non endemic counties.  
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Legends: 
Figure 1A: Distribution of patients with Presumed Ocular Tuberculosis with QGold 
Positive 
Figure 1B: Flow diagram of outcome of cohort of presumed ocular tuberculosis patients 
with positive QFT. 
Figure 2: Receiver operating characteristic curve of the binary logistic regression model 
for the prediction of treatment failure. (2A) Receiver operating characteristic curve of the 
binary logistic regression model for the prediction of treatment failure in cohort of 
patients who had ATT and had QFT >1.50. (2B) Receiver operating characteristic curve 
of the binary logistic regression model for the prediction of treatment failure in cohort of 
patients who had ATT but QFT was <1.50. (2C)  Receiver operating characteristic curve 
of the binary logistic regression model for the prediction of treatment failure in cohort of 
patients who did not have ATT and had QFT >1.50. (2D) Receiver operating 
characteristic curve of the binary logistic regression model for the prediction of treatment 
failure in cohort of patients who did not have ATT but QFT was <1.50. (2E)  
Table 1: Baseline patient demographics (ATT: Anti Tubercular Therapy) 
Table 2A: Clinical phenotypes and probability of treatment with Anti Tubercular Therapy 
(ATT) 
Table 2B: Diagnostic and therapeutic characteristics for patients based on Anti 
tubercular treatment (ATT) 
Table 3: Model of logistic regression analysis 
Table 4: Subgroup classification by oral corticosteroid therapy 
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Table 1: Baseline demographics 
  Total 
(N=213) 
ATT -ve 
(N=77) 
ATT+ve 
(N=136) 
Effect size 
(95% CI) 
P 
Age 45.99±15.61 50.91±17.62 43.21±13.65 0.51 (0.22 to 
0.79) 
0.001 
Bilaterality 124(58.2%) 41(53.25%) 83(61.03%) 1.38 (0.78 to 
2.42) 
0.269 
Male 
Gender 
122(57.3%) 42(54.54%) 80(58.82%) 1.19 (0.68 to 
2.09) 
0.544 
Ethnicity 
White  42 (19.7%) 19 (24.68%) 23 (16.91%)  0.62 (0.31 to 
1.23) 
0.171 
Asian 120 (56.3%) 35 (45.45%) 85 (62.50%) 2.00 (1.13 to 
3.53) 
0.016 
African 51(23.9%) 23 (29.87%) 28 (20.59%)  0.61 (0.32 to 
1.16) 
0.127 
ATT: Anti Tubercular Therapy, -ve: negative, +ve: positive 
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Table 2A:  Clinical phenotypes and  their likelihood  of receiving ATT 
  Total  
(N=213) 
No ATT 
(N=77) 
ATT  
(N=136) 
Effect size 
(CI95) 
P 
Retinal 
vasculitis 
54(25.4%) 12 (15.6%) 42(30.9%) 2.42        
(1.18 to 4.95) 
0.014 
Serpiginous like 
choroiditis 
10(4.7%) 0 (0.0%) 10 (7.4%)  0.015 
Choroiditis 34(16.0%) 11 (14.3%) 23(16.9%) 1.22         
(0.56 to 2.66) 
0.615 
Choroidal 
granuloma 
8(3.8%) 1 (1.3%) 7 (5.1%)
  
4.12         
(0.50 to 
34.17) 
0.263 
Panuveitis 71(33.3%) 17(22.1%) 54 (39.7%) 2.32 (1.23 to 
4.40) 
0.009 
Intermediate 
uveitis 
69 (32.4%) 38 (48.1%) 32(23.5%) 0.33         
(0.18 to 0.61) 
<0.001 
Anterior uveitis 90 (42.3%) 47(61.0%) 43 (31.6%) 0.30       (0.17 
to 0.53) 
<0.001 
ATT: Anti Tubercular Therapy 
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Table 2B: Diagnostic and treatment characteristics based on patients receiving 
Anti Tubercular therapy 
  Total  
(N=213) 
No ATT 
(N=77) 
ATT    
(N=136) 
Effect size 
(95% CI) 
P 
Chest X-
Ray 
31(14.6%) 15 (19.5%) 16 (11.8%) 0.54 (0.25 to 
1.17) 
0.115 
ESR 13.60(±11.40) 15.17(±12.17) 
 
12.69(±10.88)  0.22 (-0.06 
to 0.50) 
0.144 
QFT value 7.09 (±6.43) 7.02 (±7.22) 7.13 (±5.96) -0.02 (-0.30 
to 0.26) 
0.902 
Oral 
Steroids 
123 (57.7%) 30 (39.0%) 93 (68.4%) 3.39 (1.89 to 
6.07) 
<0.001 
ATT: Anti Tubercular Therapy, ESR=Erythrocyte sedimentation rate,                  
QFT= QuantiFERON Gold in tube test 
* - Chest X ray findings consistent with healed tuberculosis. 
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Table 3: Results of binary logistic regression model for factors predicting failure 
(n = 213; R2Nagelkerke = 0.357; C-index = 0.822; pHosmer–Lemeshow = 0.463). 
Variable Β SE of β OR 95% CI P 
Age in years -0.009 0.013 0.991 0.97 to 
1.02 
0.508 
Sex (male) 0.369 0.398 1.45 0.66 to 
3.16 
0.355 
ATT -0.208 0.437 0.812 0.35 to 
1.91 
0.633 
Oral steroids 0.607 0.466 1.835 0.74 to 
4.58 
0.193 
Anterior uveitis 1.253 0.464 3.500 1.41 to 
8.69 
0.007 
 
 
Immunosuppressive 
treatment 
3.182 0.650 24.106 6.75 to 
86.11 
<0.001 
QFT Value 
(>/=1.50) 
-1.596 0.437 0.203 0.09 to 
0.48 
<0.001 
Serpinginous-like 
choroiditis 
-0.250 1.067 0.778 0.10 to 
6.30 
0.814 
Panuveitis 0.094 0.447 1.098 0.46 to 
2.64 
0.834 
Constant -0.394 0.855 0.503 0.03 to 
1.76 
0.241 
OR: odds ratio, 95% CI: 95% confidence interval, ATT: Antitubercular therapy, 
QFT=QuantiFERON Gold in tube test. 
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Table 4: Subgroup classification by oral inmunosuppressive therapy. 
  No 
Immunosupressants 
(N=191) 
Immunosuppressive 
treatment  (N=22) 
Effect size (CI95) P 
Age 45.99 ± 15.92  45.95 ± 12.91  0.00 (-0.44 to 0.44) 0.991 
Bilaterality 105 (55.0%) 19 (86.4%) 5.19 (1.49-18.12) 0.005 
Female gender 78 (40.8%) 13 (59.1%) 2.09 (0.85 to 5.13) 0.101 
Retinal vasculitis 50 (26.2%) 4 (18.2%) 0.63 (0.20 to 1.94) 0.605 
Serpiginous like 
choroiditis 
7 (3.7%) 3 (13.6%) 4.15 (0.99 to 17.39) 0.071 
Choroiditis 30 (15.7%) 4 (18.2%) 1.19 (0.38 to 3.77) 0.760 
Choroidal 
granuloma 
7 (3.7%) 1 (4.5%)  1.25 (0.15 to 10.68) 0.588 
Panuveitis 59 (30.9%) 12 (54.5%) 2.68 (1.10 to 6.56) 0.026 
Intermediate 
uveitis 
62 (32.5%) 7 (31.8%) 0.97 (0.38 to 2.50) 0.951 
Anterior uveitis 85 (44.5%) 5 (22.7%) 0.37 (0.13 to 1.04) 0.067 
QGold Value 7.05 ± 6.47 7.48±6.21 -0.07 (-0.51 to 0.38) 0.776 
QGold Value 
≥1.50 
143 (78.1%) 18 (90.0%) 2.52 (0.56 to 11.31) 0.381 
ATT 121 (63.4%) 15 (68.2%) 1.24 (0.48 to 3.119) 0.655 
Oral steroids 101 (52.9%) 22 (100.0) 40.12 (2.40 to 
670.97) 
<0.001 
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